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Background: Insulin-like growth factors 1 and 2 (IGF1 and IGF2) and their binding proteins (IGFBPs) are expressed
in the placenta and known to regulate fetal growth. DNA methylation is an epigenetic mechanism which involves
addition of methyl group to a cytosine base in the DNA forming a methylated cytosine-phosphate-guanine (CpG)
dinucleotide which is known to silence gene expression. This silences gene expression, potentially altering the
expression of IGFs and their binding proteins. This study investigates the relationship between DNA methylation of
components of the IGF axis in the placenta and disorders in fetal growth. Placental samples were obtained from
cord insertions immediately after delivery from appropriate, small (defined as birthweight <10th percentile for the
gestation [SGA]) and macrosomic (defined as birthweight > the 90th percentile for the gestation [LGA]) neonates.
Placental DNA methylation, mRNA expression and protein levels of components of the IGF axis were determined by
pyrosequencing, rtPCR and Western blotting.
Results: In the placenta from small for gestational age (SGA) neonates (n = 16), mRNA and protein levels of IGF1 were
lower and of IGFBPs (1, 2, 3, 4 and 7) were higher (p < 0.05) compared to appropriately grown neonates (n = 37). In
contrast, in the placenta from large for gestational age (LGA) neonates (n = 20), mRNA and protein levels of IGF1 was
not different and those of IGFBPs (1, 2, 3 and 4) were lower (p < 0.05) compared to appropriately grown neonates.
Compared to appropriately grown neonates, CpG methylation of the promoter regions of IGF1 was higher in SGA
neonates. The CpG methylation of the promoter regions of IGFBP1, IGFBP2, IGFBP3, IGFBP4 and IGFBP7 was lower in
the placenta from SGA neonates as compared to appropriately grown neonates, but was unchanged in the placenta
from LGA neonates.
Conclusions: Our results suggest that changes in CpG methylation contribute to the changes in gene expression
of components of the IGF axis in fetal growth disorders. Differential methylation of the IGF1 gene and its binding
proteins is likely to play a role in the pathogenesis of SGA neonates.
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Insulin-like growth factors 1 and 2 (IGF1, IGF2) are
expressed in the placenta and are known to regulate fetal
growth [1]. While maternal IGF1 has been shown to
stimulate fetal growth by increasing the transfer of nutri-
ents to the fetus [2], fetal IGF1 is presumed to stimulate* Correspondence: v.terzidou@imperial.ac.uk
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thesis [3]. IGF1 gene ablation has been shown to reduce
fetal weight while IGF1 administration has been shown to
increase fetal weight [4]. The main role of IGF2 appears to
be mediated through its effects on cellular growth and
tissue-specific cell proliferation [5]. IGF2 overexpression in
mice causes placental and fetal overgrowth, whereas IGF2
gene deletion reduces placental and fetal weight [6, 7].
When both genes are deleted simultaneously, the effects
on fetal growth are additive [8]. Studies on placental IGF1le is distributed under the terms of the Creative Commons Attribution 4.0
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consistent [9–16]. The bioavailability of IGFs is modulated
by their seven binding proteins (IGFBP) [17]. The affinity
of IGFBP3 for IGFs is higher than other IGFBPs [18],
hence approximately 80–90 % of IGFs are bound to
IGFBP3 [19]. In pregnancy, the IGFBPs and in particular
IGFBP2, 3, 4 and 5, but not IGFBP1, are cleaved by prote-
ases, which reduce their affinity for IGFs [20, 21]. As a re-
sult, the levels of maternal IGFBP1 continue to increase
during pregnancy in a similar fashion to those of IGF1
[22]. Although IGFBP3 is the most common binding pro-
tein found in the placenta [23], IGF1 and IGFBP1 appear
to play the major role in regulating fetal growth. IGFBP1
affinity towards IGF1 is three times higher than proteo-
lyzed IGFBP3, but is lower for IGF2 [19]. Hence, the in-
creased activity of proteases during pregnancy shifts the
control of IGF action from IGFBP3 to IGFBP1.
Placental methylation is significantly lower compared
to other somatic tissues [24–26] and this has been asso-
ciated with promoting fetal development throughout
gestation [27–30]. Placental function and the intrauter-
ine environment play critical roles in fetal program-
ming [31–33], and different lines of evidence suggest a
role for epigenetic mechanisms, including genomic im-
printing and DNA methylation in this process [34, 35].
Several animal models have also suggested that altering
placental DNA methylation plays an important role in
placental and fetal growth [36].
The aim of the current study was to investigate the gen-
etic and epigenetic changes in placental IGF1/IGF2 andTable 1 Maternal and pregnancy characteristics
Variables Appropriately grown
(n = 38)
Smal
(n = 1
Maternal age (years) 31.5 (28.7–35.0) 31.5 (
Parity, n (%)
Nulliparous, n (%) 20 (52.6) 10 (6
Parous, n (%) 18 (47.4) 6 (37
Racial origin
Caucasian, n (%) 25 (65.8) 11 (6
Black, n (%) 7 (18.4) 3 (18
Other, (%) 6 (15.8) 2 (12
Smokers, n (%) 1 (2.6) 2 (12
Maternal body mass index at booking 23.0 (20.0–25.2) 22.0 (
Gestational age at delivery (weeks) 39.2 (39.0–41.0) 36.5 (
Maternal age (years) 31.5 (28.7–35.0) 31.5 (
Parity, n (%)
Nulliparous, n (%) 20 (52.6) 10 (6
Parous, n (%) 18 (47.4) 6 (37
Birthweight percentile 54.5 (21.0–76.2) 1.4 (0
Data are expressed as median (interquartile range). Comparisons between categoric
Whitney test both with post hoc Bonferroni correction. *p < 0.01 for comparisons vstheir seven binding proteins in order to understand the
“net IGF bioavailability” in pregnancies with small for ges-
tational age (SGA), large for gestational age (LGA) and ap-
propriately grown neonates.
Results
Maternal and neonatal characteristics
Seventy-four women were recruited to the study, with ap-
propriately grown (n = 38), SGA (n = 16) and LGA (n =
20) neonates. The placental mRNA and protein expression
was analysed in all cases. DNA methylation levels were
analysed in a total of 24 women (8 in each group). The
maternal and pregnancy characteristics of the study par-
ticipants are given in Table 1. Compared to appropriately
grown neonates, women with SGA neonates were deliv-
ered earlier, and women with LGA neonates had a higher
BMI (Table 1).
Placental mRNA expression and protein expression of the
IGF axis and its binding proteins
Compared to appropriately grown neonates, the placen-
tal mRNA expression of IGF1 was reduced in the SGA
group but not in the LGA group (Fig. 1). There were no
significant differences in IGF2 gene expression between
the groups. Compared to appropriately grown neonates,
the IGFBP1, 2, 3, and 4 gene expression was significantly
higher in the SGA group (p < 0.001) and lower in the
LGA group (p < 0.05). IGFBP5 and IGFBP6 expression
was not detected in the placenta samples. IGFBP7 ex-
pression was higher in SGA group (p < 0.001) and notl for gestational age
6)
Large for gestational age
(n = 20)
p value (overall)
25.2–33.7) 33.0 (30.0–37.2) 0.173
2.5) 11 (55.0) 0.8
.5) 9 (45.0)
8.8) 19 (95.0) 0.045
.8) 1 (5.0)
.4) 0 (0)
.5) 1 (5) 0.341
20.2–24.0) 26.5 (23.2–36.0)* 0.002
32.2–38.8)* 39.5 (39.0–40.0) 0.001
25.2–33.7) 33.0 (30.0–37.2) 0.173
2.5) 11 (55.0) 0.8
.5) 9 (45.0)
.3–6.8)* 98.3 (95.2–99.6)* <0.001
al and continuous variables were done by x2 or Fisher’s exact test and Mann-
. appropriately grown neonates
Fig. 1 Placental mRNA expression of the IGF axis in appropriately grown, SGA and LGA neonates. a IGF1 expression, b IGF2 expression, c IGFBP1
expression, d IGFBP2 expression, e IGFBP3 expression, f IGFBP4 expression, g IGFBP7 expression. *p < 0.05, **p < 0.005, ***p < 0.0005 when
compared to appropriately grown neonates; SGA small for gestational age, LGA large for gestational age
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grown neonates. The mRNA expression of IGF1 was posi-
tively correlated with birthweight centiles (r = 0.22, p =
0.04) (Fig. 2). Conversely, there was a significant negative
correlation between all the binding protein gene expres-
sion and birthweight percentiles (Fig. 2).
Western blotting revealed a correlation between placen-
tal protein expression and changes seen in the mRNA ex-
pression. Compared to appropriately grown neonates,0
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Fig. 2 Spearman’s correlation between placental mRNA expression and inc
centiles, b IGFBP1 expression vs. birthweight centiles, c IGFBP2 expression v
e IGFBP4 expression vs. birthweight centiles, f IGFBP7 expression vs. birthw
expression and a significant negative correlation between the binding prot
the crucial role played by their inverse relationship in controlling fetal growthere was a tendency for a lower placental IGF1 protein in
SGA group (Fig. 3a). The protein content of IGFBP2,
IGFBP3, IGFBP4 and IGFBP7 genes was significantly
higher in SGA group (IGFBP2, p < 0.005; IGFBP3, p <
0.05; IGFBP4, p < 0.05; IGFBP7, p < 0.05) while that of
IGFBP1, IGFBP2, IGFBP3 and IGFBP4 was lower in the
LGA group (IGFBP1, p < 0.05; IGFBP2, p < 0.005; IGFBP3,
p < 0.005; IGFBP4, p < 0.0005) (Fig. 3), compared to ap-
propriately grown neonates.0
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Fig. 3 (See legend on next page.)
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Fig. 3 Placental protein expression of the IGF axis in appropriately grown, SGA and LGA neonates. a IGF1 expression, b IGFBP1 expression, c
IGFBP2 expression, d IGFBP3 expression, e IGFBP4 expression, f IGFBP7 expression, g IGFBP1 expression, h IGFBP2 expression, i IGFBP3 expression,
j IGFBP4 expression. *p < 0.05, **p < 0.005, ***p < 0.0005, when compared to appropriately grown neonates. SGA small for gestational age, LGA
large for gestational age. Increased protein expression of IGFBP1, IGFBP2, IGFBP3, IGFBP4 and IGFBP7 in SGAs and decreased expression of IGFBP1,
IGFBP2, IGFBP3 and IGFBP4 in LGA neonates suggest inverse relationship of the binding protein expression with fetal growth
Nawathe et al. Clinical Epigenetics  (2016) 8:11 Page 6 of 13Promoter CpG methylation of the IGF axis and its binding
proteins
In the SGA group, all CpG sites at the IGF1 promoter
were found to be about 1.5 times hypermethylated as
compared to appropriately grown neonates (Fig. 4). Con-
versely, the three CpG sites at the IGFBP1 and IGFBP2
promoters were found to be about half as methylated as
the appropriately grown neonates, but there were no
methylation differences in the LGA group. The CpG
sites in the IGFBP3 promoter at positions 46, 47 and 50Fig. 4 Placental promoter methylation in appropriately grown, SGA and LG
b IGFBP1 promoter methylation—CpG sites 11, 12 and 13, c IGFBP2 promoter
sites 23, 24, 25, 26, 27, 28 and 29; e IGFBP3 promoter methylation—CpG sites 4
11 and 12. *p< 0.05 when compared to appropriately grown, SGA small for gewere also significantly hypomethylated in the SGA with
no differences in the LGA group (Fig. 4). However, there
were no methylation differences at sites 48 and 49 in the
IGFBP3 promoter across all the groups. CpG sites 23,
24, 26, 27 and 28 but not 25 and 29 in the IGFBP4 pro-
moter and sites 9 and 10 in the IGFBP7 promoter were
significantly hypomethylated in the SGA group, com-
pared to appropriately grown neonates, while there were
no methylation differences in the LGA group (Fig. 4).
The majority of CpG sites on the IGF1 promoter had aA neonates. a IGFF1 promoter methylation—CpG sites 1, 2 and 3;
methylation—CpG sites 9, 10, 11; d IGFBP4 promoter methylation—CpG
6, 47, 48, 49 and 50; f IGFBP7 promoter methylation—CpG sites 8, 9, 10,
stational age, LGA large for gestational age
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pression (CpG 1, r = −0.6, p = 0.007; CpG 2, r = −0.73,
p = 0.0007; CpG 3, r = −0.4, p = 0.14) (Table 2). In
addition, the majority of the CpG sites on the pro-
moters of the binding proteins IGFBP1, IGFBP2 and
IGFBP3, CpG sites 23, 26, 27, 28 and 29 on the
IGFBP4 and CpG sites 8 and 9 on the IGFBP7 pro-
moter had a significant negative correlation with their
respective mRNA expression (Table 2). No significant
correlation with their respective mRNA expression was
identified between CpG sites 24 and 25 of IGFBP4 pro-
moter and sites 10, 11 and 12 of IGFBP7 promoter.
Birthweight centiles had a significant negative correl-
ation with IGF1 promoter methylation but a significant
positive correlation with binding protein methylation
(Fig. 5).Table 2 Correlation between DNA methylation and mRNA
expression
Gene CpG number CpG location Rs p value
IGF1 1 Chr12: −102874567 −0.6275 0.007*
IGF1 2 Chr12: −102874689 −0.7377 0.0007*
IGF1 3 Chr12: −102874755 −0.4044 0.10
IGFBP1 11 Chr7: 45927583 −0.4728 0.01*
IGFBP1 12 Chr7: 45927579 −0.6349 0.0005*
IGFBP1 13 Chr7: 45927575 −0.7005 <0.0001*
IGFBP2 9 Chr2: 217497928 −0.7785 <0.0001*
IGFBP2 10 Chr2: 217497846 −0.5856 0.001*
IGFBP2 11 Chr2: 217497740 −0.6205 0.0007*
IGFBP3 46 Chr7: −45960433 −0.8086 <0.0001*
IGFBP3 47 Chr7: −45960418 −0.6627 0.0002*
IGFBP3 48 Chr7: −45960415 −0.5104 0.007*
IGFBP3 49 Chr7: −45960400 −0.4161 0.04*
IGFBP3 50 Chr7: −45960394 −0.6306 0.001*
IGFBP4 23 Chr17: 38599317 −0.5971 0.002*
IGFBP4 24 Chr17: 38599314 −0.3923 0.05
IGFBP4 25 Chr17: 38599311 0.04471 0.83
IGFBP4 26 Chr17: 38599308 −0.6726 0.0003*
IGFBP4 27 Chr17: 38599305 0.626 0.001*
IGFBP4 28 Chr17: 38599302 −0.5158 0.009*
IGFBP4 29 Chr17: 38599299 −0.1613 0.45*
IGFBP7 8 Chr4: −57976141 −0.6501 0.0006*
IGFBP7 9 Chr4: −57976145 −0.6882 0.0002*
IGFBP7 10 Chr4: −57976152 0.19 0.37
IGFBP7 11 Chr4: −57976157 −0.2764 0.19
IGFBP7 12 Chr4: −57976172 −0.05846 0.78
Spearman’s correlation between mRNA expression and DNA methylation
showed significant inverse correlation at all CpGs tested except in two
locations (24 and 25) at IGFBP4 promoter region and at three locations
(10, 11 and 12) at IGFBP7 promoter regionDiscussion
Our study has demonstrated that in pregnancies affected
by SGA, the placental IGF and IGFBP axis is altered; we
found that placental IGF1 mRNA is decreased, the IGFBPs
expression is increased and these changes are associated
with alterations in DNA methylation levels of IGF1 (hyper-
methylated) and IGFBPs (hypomethylated). These findings
indicate that epigenetic modification may play a key role in
controlling fetal growth. In contrast, in LGA pregnancies,
the differences in gene expression could not be explained
by corresponding changes in the methylation of the re-
spective gene promoters.
Various reports have described differences in placental
IGF and IGFBP mRNA expression in fetuses affected by
growth disorders. However, these studies were limited by
the small sample size, the number of binding proteins
being investigated and the type of tissue being examined
i.e. either the placenta [10–12, 37, 38] or umbilical blood
[39–41]. In our study, we have assessed the placental
IGF axis at the epigenetic, transcriptional and translation
levels in pregnancies resulting in appropriate, small and
large neonates. The crucial role played by IGF1 in fetal
growth and programming is supported by animal studies
where IGF1 knockout mice not only had a reduced birth-
weight but also continued to weigh less throughout their
lives [7]. We found IGF1 mRNA expression was lower in
SGA group, which is consistent with previous studies [10,
26]. It is well known that altered DNA methylation can
contribute to disease pathogenesis [42, 43]. Indeed, we
found that the IGF1 gene promoter was hypermethylated
in the placenta of SGA neonates. Importantly, IGF1 mRNA
expression had a significant positive correlation with birth-
weight, while IGF1 promoter methylation had a significant
negative correlation. These relationships between gene ex-
pression, promoter methylation and birthweight suggest
that the epigenetic control of IGF1 expression has a causa-
tive role in the pathogenesis of fetal growth restriction. In
agreement with other studies, we found that IGF1 was not
differentially expressed in LGA neonates and IGF2 expres-
sion was similar across all the subgroups [44, 45].
We found elevated mRNA and protein levels of IGFBP1,
IGFBP2, IGFBP3, IGFBP4 and IGFBP7 in placenta of SGA
neonates and decreased expression of IGFBP1, IGFBP2,
IGFBP3 and IGFBP4 in the LGA group. Corresponding to
these changes in gene expression, the promoters of the re-
spective genes were hypomethylated in the SGA. There
was a significant negative correlation between IGFBPs 1,
2, 3, 4 and 7 mRNA expression and birthweight while pro-
moter methylation of all the binding proteins showed a
significant positive correlation with it. While some studies
have shown an inverse correlation of IGFBP1 and IGFBP2
with birthweight [38, 46], there are conflicting data re-
garding IGFBP3 gene expression and a paucity of data de-
scribing IGFBP4, IGFBP5, and IGFBP6 expression in the
Fig. 5 Spearman’s correlation between placental promoter CpG methylation and increasing order of birthweight centiles. a IGF1 methylation vs.
birthweight centiles, b IGFBP1 methylation vs. birthweight centiles, c IGFBP2 methylation vs. birthweight centiles, d IGFBP3 methylation vs. birthweight
centiles, e IGFBP4 methylation vs. birthweight centiles, f IGFBP7 methylation vs. birthweight centiles. A significant negative correlation between IGF1
mRNA expression and a significant positive correlation between the binding protein expression with increasing order of birthweight centiles could
reflect the indirect role played by DNA methylation relationship in controlling fetal growth by controlling gene expression of the IGF axis
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and IGFBP6 could not be detected in our samples; this
may be due to their expression being restricted to the de-
cidua [1, 49]. IGFBP7 gene expression has not been previ-
ously investigated in small or large neonates and has not
been detected in human placenta. An inverse correlation
between promoter methylation and mRNA expression
suggests that DNA methylation plays a crucial role in the
gene expression of the binding proteins and therefore
impacting in the pathogenesis of small fetal size. There
were no methylation differences in the promoters of IGF1
and the binding proteins in the LGA group. It is possiblethat DNA methylation plays an important role in the
pathogenesis of small fetal size while other mechanisms,
like microRNA or histone modifications, may be import-
ant in the pathogenesis of macrosomia.
Another modification of cytosine is called 5-
hydroxymethylcytosine (5-HMC) which is also known to
play a role in activating or silencing genes [50]. Liu et al.
have recently shown significant differences in 5-HMC
concentrations in different tissues of the human body with
the highest concentration (0.4–0.6 %) found in the brain,
liver, kidney and colorectal tissues while lowest concentra-
tion (0.02 %) found in the placenta [51]. Piyasena et al.
Nawathe et al. Clinical Epigenetics  (2016) 8:11 Page 9 of 13[52] have suggested that placental 5-methylcytocine and
5-hydroxythethylcytocine patterns are associated with the
expression of imprinted genes linked with birthweight. Fu-
ture work can investigate placental 5-HMC in the IGF
system-related genes in appropriately grown, small and
large neonates.
Conclusions
We have found that IGF1 gene is underexpressed and
IGFBP1, IGFBP2, IGFBP3, IGFBP4 and IGFBP7 are over-
expressed in the placenta of SGA neonates, and these dif-
ferences could be partly explained by the inverse changes
in promoter methylation. In contrast, placental IGFBP1,
IGFBP2, IGFBP3 and IGFBP4 genes are underexpressed
in pregnancies with LGA neonates, but these differences
are not associated with changes in DNA methylation; fur-
ther studies are required to identify the mechanisms re-
sponsible for their gene expression.
Methods
We obtained placental biopsies, immediately following
delivery, from women that delivered appropriate size ne-
onates, small for gestational age (SGA) neonates, defined
as birthweight <10th percentile for gestation, adjusted
for gestational age, and large for gestational age (LGA)
neonates, defined as birthweight >90th percentile for
gestation, adjusted for gestational age [53]. Placental
samples were collected from the fetal side and washed
with PBS to remove contaminants. Areas which ap-
peared calcified or encored were excluded, and samples
were stored at −80 °C until further analysis. Umbilical
cord tissue, amniotic membranes and decidua were ex-
cluded. All pregnancies were dated by a first trimester
scan at 11–13 weeks of gestation. Booking maternal
body mass index (BMI) was calculated as weight/height
in square meter. All patients gave a written informed
consent form, and the study was approved by the NRES
Committee London—Central REC ref number: 11/LO/
1315.
RNA extraction, cDNA preparation and real-time PCR
RNA extraction was performed using RNeasy Mini Kit
(Qiagen, Germany). Any contaminating DNA was removed
by DNaseI (Invitrogen) treatment room temperature for
15 min, and complementary deoxyribonucleic acid (cDNA)
was prepared by using the MMLV kit (Sigma®, Cat No.
M1302) according to the manufacturer’s instructions by re-
verse transcription of 1 μg of RNA. The cDNA was stored
at −20 °C until further analysis. A 2 μl of cDNA was added
to 8 μl of reaction mix to make a total of 10 μl per well.
The reaction mix consisted of 5 μl of SYBR Green {Sigma®,
Cat No QR0100}, 0.2 μl of ROX Reference Dye (Sigma®,
Cat No R4526), 300 nM of each primer, and RNase free
water to make up the remaining volume. All primers wereoptimised prior to cDNA amplification. Four such wells
were cleaned up using the QIAquick PCR purification kit
according to the manufacturer’s instructions (Qiagen®).
Serial dilutions from the purified DNA in the ratio of 1:10
were made which were then used in duplicate in the real-
time PCR reactions for the respective gene. The steps of
the quantification PCR included initial denaturation at 94 °
C for 2 min following which samples were subjected to 40
amplification cycles comprising of denaturation at 95 °C
for 15 s, annealing and elongation of each gene for 60 s.
All the mRNA data was expressed as a relative quantifica-
tion to the total amount of similarly expressed L19 gene.
The results of the melt curve analysis were verified further
by electrophoresis on 1 % agarose gel and photographed on
UV light illuminator (Clare Chemical Research). A negative
control was included per gene in the reaction.
Primers
The primers were designed using the protein encoding
transcripts from www.ensembl.org [54] and Primer3 (ver-
sion 0.4.0) at http://frodo.wi.mit.edu/. All the primers were
between 80 and 150 bp. The primers were checked using
Primer-BLAST at http://blast.ncbi.nlm.nih.gov/ to ensure
100 % maximum identification of the nucleotide se-
quences. The primers were IGF1F:5′-CAGCAGTCTTCC
AACCCAT-3′, IGF1R: 5′-ACAGCGCCAGGTAGAAGA
G-3′; IGF2F:5′-CAATATGACACCACCGTGCT-3′, IGF2
R:5′-GGACTGCTTCCAGGTGTCAT-3′; IGFBP1F:5′-CT
GCCAAACTGCAACAAGAA-3′, IGFBP1R:5′-GAGACC
CAGGGATCCTCTTC-3′; IGFBP2F:5′-ATGGCGATGAC
CATCAGA-3′, IGFBP2R:5′-ACCTGGTCCAGTTCCTGT
TG-3′; IGFBP3F:5′-CAGAGACTCGAGCACAGCAC-3′,
IGFBP3R:5′-GCCGCCTAAGTCACAAAGTC-3′; IGFBP4
F:5′-CCCACGAGGACCTCTACATC-3′, IGFBP4R:5′-AT
CCAGAGCTGGGTGACACT-3′; IGFBP5F:5′-AGCAGC
AACGTTGAGTGATG-3′, IGFBP5R:5′-GATGAAATGA
GTGGCGTCCT-3′; IGFBP6F:5′-GCTGTTGCAGAGGA
GAATCC-3′, IGFBP6R:5′-GGTAGAAGCCTCGATGGT
CA; IGFBP7F:5′-CATCCAATTCCCAAGGACAG-3′, IGF
BP7R:5′-TATAGCTCGGCACCTTCACC-3′; L19F:5′-GC
GGAAGGGTACAGCCAAT-3′, L19R:5′-GCAGCCGGC
GCAAA-3′.
Protein extraction, western blot and immunodetection
Placental samples were homogenised in modified RIPA buf-
fer containing 1 % Triton ×100, 1 % sodium deoxycholate,
0.1 % SDS, 150 mM sodium chloride, 10 mM Tris (pH 7.4)
and 1 mM EDTA with 1 mM of PMSF and protease inhibi-
tor cocktail (Sigma-Aldrich) which was used to lyse the pla-
cental samples. The lysate was centrifuged at 13,000×g for
30 min at 4 °C and the supernatant extracted to obtain
whole-cell protein. The protein extracts were quantified by
the Lowry method (Bio-Rad). Protein samples were ali-
quoted and then stored at −80 °C to avoid freeze-thaw
Nawathe et al. Clinical Epigenetics  (2016) 8:11 Page 10 of 13cycles. Denaturation of proteins was performed at 80 °C for
10 min with loading dye consisting of 3 % glycerol, 3 %
SDS, 1 % Bromophenol blue and β-mercaptoethanol. Equal
amount of proteins (50 μg) were run either on a 10 % SDS-
Polyacrylamide gel for 80 min at 120 V, and were trans-
ferred to polyvinylidene difluoride (PVDF) membranes
(Millipore) for 90 min at 300 mA or on a Bio-Rad Criterion
TGX gel, 26-well midi gel (Cat No. 567-1085) for 80 min at
120 V and transferred for 7 min on a Tran-Blot® Turbo™
Midi PVDF Transfer Pack (Cat No. 170-4157). Membranes
were incubated in 5 % blocking buffer for 1 h at room
temperature and hybridized with primary antibody over-
night at 4 °C. Secondary antibody incubation was then car-
ried out the following day and immunodetection using
ECL2 or ECL (Fisher Scientific). The primary antibodies
were IGF1—Abcam, cat no. Ab9572; IGFBP1—Santa Cruz,
cat no. Sc-55474, IGFBP2—Abcam, cat no. Ab109284;Table 3 Localisation of the CpG sites in the genome
Gene CpG number CpG location Transcription start site (TSS) Forw
IGF1 1 Chr12:
−102874567
102874323 GATA
IGF1 2 Chr12:
−102874689
102874323 GATA
IGF1 3 Chr12:
−102874755
102874323 GATA
IGFBP1 1 Chr7: 45927583 45928093 TTGA
IGFBP1 2 Chr7: 45927579 45928093 TTGA
IGFBP1 3 Chr7: 45927575 45928093 TTGA
IGFBP2 9 Chr2:217497928 217498172 TGGG
IGFBP2 10 Chr2:217497846 217498172 TGGG
IGFBP2 11 Chr2:217497740 217498172 TGGG
IGFBP3 46 Chr7: −45960433 45960866 AGAA
IGFBP3 47 Chr7: −45960418 45960866 AGAA
IGFBP3 48 Chr7: −45960415 45960866 AGAA
IGFBP3 49 Chr7:-45960400 45960866 AGAA
IGFBP3 50 Chr7: −45960394 45960866 AGAA
IGFBP4 23 Chr17: 38599317 38599681 GGG
IGFBP4 24 Chr17: 38599314 38599681 GGG
IGFBP4 25 Chr17: 38599311 38599681 GGG
IGFBP4 26 Chr17: 38599308 38599681 GGG
IGFBP4 27 Chr17: 38599305 38599681 GGG
IGFBP4 28 Chr17: 38599302 38599681 GGG
IGFBP4 29 Chr17: 38599299 38599681 GGG
IGFBP7 8 Chr4: −57976141 57975928 GGA
IGFBP7 9 Chr4: −57976145 57975928 GGA
IGFBP7 10 Chr4: −57976152 57975928 GGA
IGFBP7 11 Chr4: −57976157 57975928 GGA
IGFBP7 12 Chr4: −57976172 57975928 GGA
Target CpGs were identified within 500 bp from the transcription start sites of the rIGFBP3—Santa Cruz, cat no. Sc-6004; IGFBP4—Santa
Cruz, cat no. Sc-6005; IGFBP7—Santa Cruz, cat no. Sc-
13095; β-actin—Abcam, cat no. Ab6276; positive control—-
liver (human) tissue lysate—Abcam, cat no. Ab29889.Gene promoter assays
The CpG assays were designed using the Pyromark CpG
software (Qiagen), and the genomic sequences were ex-
tracted from the USCS genome browser at www.geno-
me.uscs.edu [55]. The CpGs were identified from the
promoter region of each of the target gene. The pro-
moter regions were identified from sequences up to
500 bp upstream of the transcription start sites (TSS)
(Table 3). To address epigenetic events associated with
fetal growth disorders, we analysed CpG methylation at
three sites in the IGF1, IGFBP1 and IGFBP2 promoterard primer Reverse primer (biotinylated)
GGAAATAGTTGGGGGAATATTTGT AATCTACTTTACCCCAATCACTTCAA
GGAAATAGTTGGGGGAATATTTGT AATCTACTTTACCCCAATCACTTCAA
GGAAATAGTTGGGGGAATATTTGT AATCTACTTTACCCCAATCACTTCAA
GTAGGGTTTTGGGTGTATTAGTAA AACCCAAACTCTAAACAAATAATAAT
GTAGGGTTTTGGGTGTATTAGTAA AACCCAAACTCTAAACAAATAATAAT
GTAGGGTTTTGGGTGTATTAGTAA AACCCAAACTCTAAACAAATAATAAT
GGTTTAGGGTGTTAAG CTAACCCCTAAAAAACACAAAAAACAT
GGTTTAGGGTGTTAAG CTAACCCCTAAAAAACACAAAAAACAT
GGTTTAGGGTGTTAAG CTAACCCCTAAAAAACACAAAAAACAT
GTAGGGGTGGTTTAGGATA AAACCCTATATACCAATTTCCC
GTAGGGGTGGTTTAGGATA AAACCCTATATACCAATTTCCC
GTAGGGGTGGTTTAGGATA AAACCCTATATACCAATTTCCC
GTAGGGGTGGTTTAGGATA AAACCCTATATACCAATTTCCC
GTAGGGGTGGTTTAGGATA AAACCCTATATACCAATTTCCC
GTTTAGGTTTAGAGGTATTTTGG ACCCCCAACCCCTTCCCAAAAAT
GTTTAGGTTTAGAGGTATTTTGG ACCCCCAACCCCTTCCCAAAAAT
GTTTAGGTTTAGAGGTATTTTGG ACCCCCAACCCCTTCCCAAAAAT
GTTTAGGTTTAGAGGTATTTTGG ACCCCCAACCCCTTCCCAAAAAT
GTTTAGGTTTAGAGGTATTTTGG ACCCCCAACCCCTTCCCAAAAAT
GTTTAGGTTTAGAGGTATTTTGG ACCCCCAACCCCTTCCCAAAAAT
GTTTAGGTTTAGAGGTATTTTGG ACCCCCAACCCCTTCCCAAAAAT
AAGGGGAGAAATTAGAGGG TCCTACTCCATCCCCAAT
AAGGGGAGAAATTAGAGGG TCCTACTCCATCCCCAAT
AAGGGGAGAAATTAGAGGG TCCTACTCCATCCCCAAT
AAGGGGAGAAATTAGAGGG TCCTACTCCATCCCCAAT
AAGGGGAGAAATTAGAGGG TCCTACTCCATCCCCAAT
espective genes
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in the IGFBP4 promoter regions (Table 2).
Bisulphite modification
PureLink Genomic DNA extraction kit (Invitrogen,
K1820-02) was used for genomic DNA extraction. EZ
DNA Methylation-Gold TM Kit (Zymo Research, Irvine,
CA, USA) was used for sodium bisulphite conversion.
Approximately 500 ng of genomic DNA was bisulphite
modified by incubating at 98 °C for 10 min and 64 °C
for 2 h and 30 min. The product was desulphonated,
washed and eluted in 10 μl of elution buffer. A 2 μl of
bisulphite-modified genomic DNA (approximately 500 ng)
was amplified in a PCR mix containing 2 μl of forward and
reverse primer, 12.5 μl of FastStart Taq DNA Polymerase
(Lifescience Roche, cat no. 12032929001) and 10.5 μl of
water. DNA amplification in a thermocycler was per-
formed by following these PCR conditions: 1 cycle at
95 °C for 6 min, followed by 40 cycles of 95 °C for 30 s,
annealing temperature of 55 to 59 °C (depending on
primer pair) for 30 s and 72 °C for 30 s, followed by
1 cycle at 72 °C for 30s.
Pyrosequencing
PyroMark Q96 ID (Qiagen) was used for pyrosequencing
analysis. A 10 μl of biotinylated DNA obtained with the
PyroMark CpG Assays were complexed with 2 μl Streptavi-
din Sepharose High Performance beads (GE Healthcare) in
a solution containing 30 μl of water and 38 μl PyroMark
Binding Buffer (Qiagen) per reaction. After vortexing the
mixture for 10 min at room temperature, the beads were
washed using the PyroMark Q96 Vacuum Workstation
(Qiagen). Beads were then washed in ethanol for 5 s and
placed for 5 s in 0.2 M NaOH. The beads were further
washed for 5 s in PyroMark Wash Buffer (Qiagen) to ensure
that only single-stranded DNA remained attached to the
beads. Beads were then placed on a sequencing plate con-
taining 12 μl of the appropriate sequencing primers from
the PyroMark CpG Assays resuspended in PyroMark An-
nealing Buffer (Qiagen). The plate was heated for 5 min at
80 °C in a heating block and then allowed to cool for 2 min
before loading it on the pyrosequencer. Assay efficiency was
validated by 0 and 100 % methylated DNA (CpGenome
Universal Methylatated DNA, 10 μg, Millipore, S7821). The
methylation data was analysed by Pyro Q-CpG software
1.0.6.
All the reverse primers were biotinylated. The primers
used were IGF1F: 5′-GATAGGAAATAGTTGGGGGAAT
ATTTGT-3′, IGF1R: 5′-AATCTACTTTACCCCAATCAC
TTCAA-3′; IGFBP1F:5′-TTGAGTAGGGTTTTGGGTGT
ATTAGTAA-3′, IGFBP1R:5′-AACCCAAACTCTAAACA
AATAATAAT-3′; IGFBP2F:5′-TGGGGGTTTAGGGTGT
TAAG-3′, IGFBP2R:5′-CTAACCCCTAAAAAACACAAA
AAACAT-3′; IGFBP3F:5′-AGAAGTAGGGGTGGTTTAGGATA-3′, IGFBP3R:5′-AAACCCTATATACCAATTTCCC
-3′; IGFBP4F:5′-GGGGTTTAGGTTTAGAGGTATTTTG
G-3′, IGFBP4R:5′-ACCCCCAACCCCTTCCCAAAAAT-3
′; IGFBP7F:5′-GGAAAGGGGAGAAATTAGAGGG-3′, I
GFBP7R:5′-TCCTACTCCATCCCCAAT-3′.
Statistical methods
Kolmogorov-Smirnov test was used to determine normal-
ity of the data. Data were expressed as median (interquar-
tile range). Comparison between groups for continuous
variables was by Student’s t test, Mann-Whitney U test,
one-way analysis of variance and Kruskal-Wallis test for
normally and not normally distributed data. Categorical
data were compared using x2test. Univariate analyses were
used to investigate the association between birthweight
percentiles and different variables. Statistical analysis was
performed using Graphpad Prism 5.0 (Sandiego, CA,
USA) and results were considered significant if p value
was <0.05.
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